Recent Updates
Recently added Catalysts
PRCT Positive Sentiment Score: 75/100

PROCEPT BioRobotics to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025

Key Takeaway: PROCEPT BioRobotics will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on December 2, 2025. The management's participation highlights the company's commitment to advancing robotic solutions for urology, particularly in treating benign prostatic hyperplasia (BPH). The conference presentation will be accessible via a live webcast, demonstrating the company's focus on investor relations. PROCEPT BioRobotics is recognized for its innovative AQUABEAM and HYDROS robotic systems which are designed to enhance patient care outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • PROCEPT BioRobotics is presenting at a major healthcare conference, indicating visibility in the market.
  • The company continues to advance its mission to improve BPH treatment with innovative robotic solutions.
  • Strong clinical evidence supports the benefits of their Aquablation therapy, showing potential for growth and acceptance.

Full Press Release Details

SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 37th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Tuesday, December 2 at 8:30 a.m. Eastern Time.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
VP, Investor Relations and Business Operations

Frequently Asked Questions

When will PROCEPT BioRobotics present at the Piper Sandler Conference?

PROCEPT BioRobotics will present on December 2 at 8:30 a.m. Eastern Time.

Where can I watch the webcast of the presentation?

The webcast will be available on the Company's 'Investors' section of their website.

What does PROCEPT BioRobotics aim to revolutionize?

The company aims to revolutionize BPH treatment with advanced robotic solutions.

What is the AQUABEAM® system used for?

The AQUABEAM® system is designed for effective treatment of BPH in men.

How many publications support Aquablation therapy?

Over 150 peer-reviewed publications support the benefits of Aquablation therapy.

Last updated: Nov 20, 2025